Business ❯ Pharmaceuticals

Market Competition

Obesity Drugs Novo Nordisk Eli Lilly Weight Loss Drugs Obesity Treatments Rivalry Bidding Wars Industry Trends Weight Loss Weight Loss Medications Revenue GSK Market Dominance Pricing Strategies Johnson & Johnson Generic Drugs Biosimilars Investor Relations Industry Players Financial Performance Corporate Restructuring Job Cuts Workforce Management Mergers and Acquisitions Sales Performance Major Players Regulatory Issues Product Development Pricing Pharmacy Benefit Managers Vaccine Market Eli Lilly and Novo Nordisk Drug Sales Drug Development Drug Pricing Product Marketing Legal Issues

Novo Nordisk Sues Lilly Over Weight‑Loss Ads as GLP‑1 Rivalry Intensifies

The case seeks to curb Eli Lilly’s consumer ads and could change how head‑to‑head trial results are shown to patients and prescribers.

FDA Expands GSK’s Arexvy to High-Risk Adults 18–49, Completing Trio of RSV Vaccines for Younger At‑Risk Group

Viking Therapeutics' Obesity Drug Moves Into Phase 3 as Investors Weigh Upside

House Panel Presses PBMs, Demands Details on Trump ‘Most Favored Nation’ Drug Deals

Novo Nordisk Foundation Installs Lars Rebien Sørensen as Chair After Shareholder Vote

Pfizer Closes Metsera Buyout, Adding GLP-1 Assets in Cash-Plus-CVR Deal

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws

Pfizer Wins Early U.S. Antitrust Clearance for Metsera Deal as Novo’s Higher Bid Pressures Timeline

Pfizer to Buy Metsera in Up to $7.3 Billion Obesity Bet